PTC Therapeutics (PTCT) Revenue & Revenue Breakdown
PTC Therapeutics Revenue Highlights
Latest Revenue (Y)
$937.82M
Latest Revenue (Q)
$186.70M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
United States
PTC Therapeutics Revenue by Period
PTC Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $937.82M | 34.20% |
| 2022-12-31 | $698.80M | 29.75% |
| 2021-12-31 | $538.59M | 41.45% |
| 2020-12-31 | $380.77M | 24.04% |
| 2019-12-31 | $306.98M | 15.96% |
| 2018-12-31 | $264.73M | 36.19% |
| 2017-12-31 | $194.39M | 135.04% |
| 2016-12-31 | $82.70M | 124.95% |
| 2015-12-31 | $36.77M | 60.11% |
| 2014-12-31 | $22.96M | -26.70% |
| 2013-12-31 | $31.33M | 8.85% |
| 2012-12-31 | $28.78M | -70.92% |
| 2011-12-31 | $98.96M | - |
PTC Therapeutics generated $937.82M in revenue during NA 2023, up 34.20% compared to the previous quarter, and up 354.25% compared to the same period a year ago.
PTC Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $186.70M | -11.14% |
| 2024-03-31 | $210.12M | -31.57% |
| 2023-12-31 | $307.06M | 56.20% |
| 2023-09-30 | $196.58M | -8.06% |
| 2023-06-30 | $213.81M | -2.98% |
| 2023-03-31 | $220.38M | 31.64% |
| 2022-12-31 | $167.41M | -22.90% |
| 2022-09-30 | $217.13M | 31.17% |
| 2022-06-30 | $165.53M | 11.29% |
| 2022-03-31 | $148.74M | -9.98% |
| 2021-12-31 | $165.23M | 19.09% |
| 2021-09-30 | $138.74M | 18.91% |
| 2021-06-30 | $116.68M | -1.07% |
| 2021-03-31 | $117.94M | -0.78% |
| 2020-12-31 | $118.86M | 0.39% |
| 2020-09-30 | $118.40M | 57.37% |
| 2020-06-30 | $75.24M | 10.23% |
| 2020-03-31 | $68.26M | -29.24% |
| 2019-12-31 | $96.46M | 35.07% |
| 2019-09-30 | $71.42M | -16.49% |
| 2019-06-30 | $85.52M | 59.61% |
| 2019-03-31 | $53.58M | -37.94% |
| 2018-12-31 | $86.34M | 61.11% |
| 2018-09-30 | $53.59M | -22.04% |
| 2018-06-30 | $68.74M | 22.62% |
| 2018-03-31 | $56.06M | -28.15% |
| 2017-12-31 | $78.03M | 86.44% |
| 2017-09-30 | $41.85M | -12.74% |
| 2017-06-30 | $47.96M | 80.67% |
| 2017-03-31 | $26.55M | 5.38% |
| 2016-12-31 | $25.19M | 9.59% |
| 2016-09-30 | $22.99M | 47.04% |
| 2016-06-30 | $15.63M | -17.26% |
| 2016-03-31 | $18.89M | 24.17% |
| 2015-12-31 | $15.22M | 55.69% |
| 2015-09-30 | $9.77M | 53.49% |
| 2015-06-30 | $6.37M | 17.77% |
| 2015-03-31 | $5.41M | -53.40% |
| 2014-12-31 | $11.60M | 1355.71% |
| 2014-09-30 | $797.00K | -43.79% |
| 2014-06-30 | $1.42M | -84.50% |
| 2014-03-31 | $9.15M | 132.70% |
| 2013-12-31 | $3.93M | -74.57% |
| 2013-09-30 | $15.46M | 163.39% |
| 2013-06-30 | $5.87M | -3.37% |
| 2013-03-31 | $6.07M | 2.60% |
| 2012-12-31 | $5.92M | -2.06% |
| 2012-09-30 | $6.04M | -0.36% |
| 2012-06-30 | $6.06M | -43.60% |
| 2012-03-31 | $10.75M | - |
PTC Therapeutics generated $186.70M in revenue during Q2 2024, up -11.14% compared to the previous quarter, and up 84.72% compared to the same period a year ago.
PTC Therapeutics Revenue Breakdown
PTC Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 19 | Dec 18 |
|---|---|---|---|
| Collaboration Revenue | $100.03M | - | - |
| Manufacturing | $7.69M | - | - |
| Product | - | $291.31M | - |
| Grant And Collaboration | - | $15.67M | - |
| Emflaza | - | - | $92.00M |
| Translarna | - | - | $171.00M |
| Early Stage Collaborations | - | - | $252.00M |
| Licensing And Collaboration Agreement | - | - | $200.00K |
| Grant | - | - | - |
PTC Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (92.86%), and Manufacturing (7.14%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing | $1.36M | $3.34M | $2.36M | $1.99M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net product revenue | $177.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | $103.11M | $91.28M | $107.26M | $82.71M | $75.24M | $68.20M | $81.41M | $71.37M | $85.48M | - | - | - | - | - |
| Grant And Collaboration | - | - | - | - | - | - | $7.52M | $35.00M | - | $63.00K | $15.05M | $47.00K | $46.00K | - | - | - | - | - |
| Royalty | - | - | - | - | - | - | $4.09M | $696.00K | - | - | - | - | - | - | - | - | - | - |
| Licensing And Collaboration Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | $100.00K | $87.50M | $100.00K | $100.00K | - |
| Early Stage Collaborations | - | - | - | - | - | - | - | - | - | - | - | - | - | $252.00M | - | - | - | - |
| Discovery Agreements | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
PTC Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Net product revenue (99.24%), and Manufacturing (0.76%).
PTC Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| United States | $531.66M | $218.30M | $187.30M | - | - |
| Non-US | $406.16M | $288.60M | $236.00M | $190.30M | - |
| Non Us | - | - | - | $194.40M | - |
| U | - | - | - | $139.00M | - |
| UNITED STATES | - | - | - | - | $116.68M |
PTC Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: United States (56.69%), and Non-US (43.31%).
Quarterly Revenue by Country
| Country | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $411.36M | $65.70M | $54.60M | $58.20M | $54.80M | $56.80M | $48.60M | $47.50M | - |
| Non-US | $194.56M | $96.50M | $115.10M | $55.70M | $76.60M | $77.00M | $79.20M | $69.70M | - |
| Non Us | - | - | - | - | - | - | - | - | $67.20M |
| U | - | - | - | - | - | - | - | - | $47.10M |
PTC Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 23: United States (67.89%), and Non-US (32.11%).
PTC Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| VKTX | Viking Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
PTCT Revenue FAQ
What is PTC Therapeutics’s yearly revenue?
PTC Therapeutics's yearly revenue for 2023 was $937.82M, representing an increase of 34.20% compared to 2022. The company's yearly revenue for 2022 was $698.8M, representing an increase of 29.75% compared to 2021. PTCT's yearly revenue for 2021 was $538.59M, representing an increase of 41.45% compared to 2020.
What is PTC Therapeutics’s quarterly revenue?
PTC Therapeutics's quarterly revenue for Q2 2024 was $186.7M, a -11.14% decrease from the previous quarter (Q1 2024), and a -12.68% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $210.12M, a -31.57% decrease from the previous quarter (Q4 2023), and a -4.66% decrease year-over-year (Q1 2023). PTCT's quarterly revenue for Q4 2023 was $307.06M, a 56.20% increase from the previous quarter (Q3 2023), and a 83.41% increase year-over-year (Q4 2022).
What is PTC Therapeutics’s revenue growth rate?
PTC Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 74.12%, and for the last 5 years (2019-2023) was 205.50%.
What are PTC Therapeutics’s revenue streams?
PTC Therapeutics's revenue streams in c 23 are Collaboration Revenue, and Manufacturing. Collaboration Revenue generated $100.03M in revenue, accounting 92.86% of the company's total revenue Manufacturing generated $7.69M in revenue, accounting 7.14% of the company's total revenue
What is PTC Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of PTC Therapeutics was Collaboration Revenue. This segment made a revenue of $100.03M, representing 92.86% of the company's total revenue.